Download the Protocol

Kisspeptin-10

Kisspeptin-10 helps control how the body releases hormones for fertility and puberty. It acts on the brain to start hormone signals that lead to testosterone, estrogen, and reproductive balance. It’s being studied for fertility research and hormone rhythm testing.

Description

• Kisspeptin-10 is a short peptide fragment derived from the kisspeptin family, the natural ligand for the GPR54 (KISS1R) receptor.
• Regulates reproductive hormone secretion through stimulation of gonadotropin-releasing hormone (GnRH) neurons.
• Investigated for its roles in fertility control, puberty initiation, and hypothalamic–pituitary–gonadal (HPG) axis regulation.

How It Works

• Binds to GPR54 receptors in the hypothalamus to stimulate GnRH release.
• Enhances downstream LH and FSH secretion from the pituitary gland.
• Indirectly influences testosterone and estradiol levels through gonadotropin signaling.

Documented Effects

• Stimulates LH surge and gonadal hormone release in both sexes.
• Plays a key role in puberty onset and reproductive axis activation.
• May support fertility research by assessing pituitary responsiveness.

Theoretical Effects

• Potential applications in reproductive hormone restoration and fertility optimization models.
• Investigated as a possible diagnostic marker for hypothalamic dysfunction.
• All non-clinical applications remain experimental.

Pharmacokinetics

• Half-life: Approximately 30–45 minutes after subcutaneous injection.
• Time to peak concentration: Around 15–30 minutes post-dose.
• Steady-state: Not typically achieved; designed for acute hormone release patterns.

Duration of Effects

• Induces transient LH and FSH release lasting 1–2 hours.
• Reproductive axis stimulation diminishes within several hours post-dose.
• Baseline hormonal levels return within 12–24 hours of discontinuation.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg of Kisspeptin-10
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~21 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• 100–200 mcg subcutaneous (SC) once daily in research settings.
• Start at 100 mcg to observe hypothalamic–pituitary response.

Common Research Range

• 100–500 mcg SC 1–2× daily depending on experimental goal.
• May be co-administered with GnRH or hCG analogs for synergy in gonadotropin studies.

Maximum Research Range

• Up to 1 mg SC per day reported in limited research without further benefit beyond pituitary saturation.

Standard Cycle Length

• 2–4 weeks in controlled protocols evaluating LH/FSH release or gonadal response.

Clinical Notes

• Administered subcutaneously into abdominal fat using insulin syringes.
• Best given in the morning or early evening to align with natural LH pulse timing.
• May be stacked cautiously with hCG or GnRH analogs under controlled conditions.
• Stable for about 21 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Possible transient flushing or lightheadedness due to acute hormone surge.
• Use sterile technique and confirm peptide purity.
• Research compound only; not for therapeutic human use.